Powered by

Lipocine talks up interim data from small NASH study

Jan 17, 2019 - FierceBiotech

Lipocine has shared interim data from a small clinical trial of its NASH candidate LPCN 1144. Shares in the nanocap biotech shotup more than 100% in premarket tradingbefore falling away somewhat as people dug deeper into the data.

Salt Lake City-based Lipocine framed results from the single-arm, open-label trial as evidence that its oral prodrug of bioidentical testosterone can deliver “meaningful” reductions in liver fat. To make its case, Lipocine singled out nine participants with b...